1-5 of 5
Stéphanie Dulucq, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study.

Franck Emmanuel Nicolini, MD PhD, Stephanie Dulucq, PhD, Joelle Guilhot, PhD, Gabriel Etienne, MD PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 462.
https://doi.org/10.1182/blood-2018-99-113029
Published: 2018
Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3014.
https://doi.org/10.1182/blood-2018-99-113044
Published: 2018
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)

Delphine Rea, MD, Jean-Michel Cayuela, PhD, Stephanie Dulucq, PhD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 318.
https://doi.org/10.1182/blood.V130.Suppl_1.318.318
Published: 2017
Journal Articles

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Ingmar Glauche, PhD, Hendrik Liebscher, Christoph Baldow, Matthias Kuhn, Philipp Schulze, Tom Haehnel, Astghik Voskanyan, PhD, Joelle Guilhot, PhD, Stéphanie Dulucq, PhD, Nikolas von Bubnoff, MD, Susanne Saussele, MD, Satu Mustjoki, MD PhD, Philipp J. Jost, MD, Francois Guilhot, MD PhD, François-Xavier Mahon, MD PhD, Ingo Roeder, PhD
Journal: Blood
Blood (2016) 128 (22): 3099.
https://doi.org/10.1182/blood.V128.22.3099.3099
Published: 2016